Lundbeck has initiated phase I trial of acquired candidate

The first patients have been recruited and dosed in a phase I study with a potential new treatment for neurological conditions, Lu AG22515, which Lundbeck acquired last October.

In October, Lundbeck bought a phase I ready candidate from Aprilbio. Now, it's been sent to clinic | Photo: Mik Eskestad/ERH

For the first time, a person has been dosed with Lu AG22515, a candidate that Lundbeck acquired for USD 16m upfront payment from South Korean biotech company Aprilbio in October last year, in a deal which also included potential milestone payments of USD 432m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs